The Killer Instinct: Using natural killer therapy to treat Alzheimer’s - An Interview with Dr. Vincent DeOrchis

DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis MD MS FAAN, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s.

In October 2023, pharmaceutical company NKGen Biotech released data from its Phase I clinical trial on the use of its investigational natural killer therapy, SNK01, to treat patients with Alzheimer’s disease. Though the study was small and designed to primarily assess SNK01’s safety, data indicate that the therapy may do more than slow the progression of Alzheimer’s disease. The FDA has also granted Compassionate Use to SNK01 and the therapy is currently being used to treat a patient with Alzheimer’s.